Regeneron slumps as Wells Fargo cuts on COPD trial data

1 day ago 1

Healthcare
On the Move

Chronic Obstructive Pulmonary Disease COPD Concept

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic obstructive pulmonary disease (COPD), prompted

Recommended For You

More Trending News

Read Entire Article

Regeneron slumps as Wells Fargo cuts on COPD trial data

Recommended For You

More Trending News

Related

Actuate Therapeutics: Elraglusib trial meets key endpoint in...

Trump administration is said to move to ease capital rules f...

Meyer Burger files for insolvency for 2 subsidiaries in Germ...

SEC raises concerns over crypto ETFs offering staking reward...

Elon Musk denies report alleging frequent ketamine use

Soaring U.S. debt doesn’t just put America at risk. It could...

Google plans to challenge antitrust ruling on search monopol...

Canadian Pacific Kansas City receives ruling on labor pacts ...

JPMorgan’s Jamie Dimon warns about a 'crack' in the U.S. bon...

Key deals this week: EOG Resources, VivoPower, Servotronics,...

Markets poised for ‘big breakout/breakdown’ as dollar weaken...

Biden-era green energy projects scrapped by Trump, including...

ASUS ExpertBook P1 Review: Practical power for everyday task...

SA Asks: What are the best tech ETFs right now?

78% of companies beat EPS estimates this week: Earnings Scor...

Judge weighs limits on Google’s search dominance amid AI dis...

Jamie Dimon says ‘don’t put a good foot forward, put the tru...

Agco falls as Citi downgrades shares on valuation

UnitedHealth posts worst monthly drop since 2009 amid negati...

Retail bots are said to swarm S&P 500 options at predictable...

Trending

Popular

صعود نماینده ناین‌بال ایران به جمع ۸ بازیکن برتر جهان و کسب ...

تصمیم مهم درباره سهمیه بازیکنان خارجی